Shares were up 13%—erasing losses in the year to date—after the company raised its annual guidance for the second time this year, citing strong U.S. demand for its blockbuster drug.
Source link
UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
Date:
More like thisRelated
Goldman Sachs teams with OpenAI, Meta in small business AI push
Artificial intelligence is already a huge business for Wall...
Russia hits Ukraine with missiles, drones after agreeing to peace talks
Russian attacks on Ukraine's capital with ballistic missiles and...
Ella Langley Performs Dolly Parton’s ‘Jolene’ at Tribute: WATCH
Ella Langley honored Dolly Parton with a performance of...
Transfer rumors, news: Man United consider defensive clearout in summer
Oct 22, 2026, 03:32 AM ETManchester United are considering...